Navigation Links
Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors

NEW BRUNSWICK, N.J., June 9 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced the appointment, effective June 8, 2009, of its current Board member, Dr. Harlan Waksal, M.D., to serve as Chairman of the Board, succeeding Mr. Rudolf Stalder, who has been the Company's Chairman since January 2000. Mr. Stalder will continue serving on the Board and also serve as a member of a newly formed Executive Committee that includes Dr. Harlan Waksal, Mr. Christopher Forbes and Mr. Rudolf Stalder.

Dr. Waksal joined the Board of Senesco in October 2008. Dr. Waksal is President and sole Proprietor of Waksal Consulting L.L.C. in Montclair, NJ. From 1984 through July 2003, he was with ImClone Systems Inc., New York, NY, serving most recently as President, Chief Executive Officer and Chief Operating Officer.

Dr. Waksal is a member of the Board of Trustees of Oberlin College Ohio, a member of the Board of Trustees and chair of the New Jersey Region of the American Committee for the Weizmann Institute of Science in New York, and a member of the Board of Trustees of the Montclair Art Museum.

The Board is also pleased to announce, effective June 8, 2009, the appointment of Mr. Warren J. Isabelle, CFA to the Board. Mr. Isabelle is a founder and principal of Ironwood Investment Management L.L.C., located in Boston, MA. From 1983-1997, Mr. Isabelle was with Pioneer Management Corporation where he served most recently as Director of Research and Head of U.S. Equities. Mr. Isabelle also serves as a member of the Public Board and the Investment Committee of the University of Massachusetts Foundation.

Mr. Stalder commented, "With Senesco's groundbreaking technologies, its research focus on human health and its plans to move diligently into clinical trials with a Multiple Myeloma cancer project, the recent addition of Dr. Waksal to Senesco's Board gave us a unique opportunity to ask him to take on these new responsibilities as Chairman of the Board. His experience in this area will best serve our efforts moving forward. We are very pleased about his acceptance of this significant role."

Dr. Waksal commented about his new responsibilities, "I am excited to take on this new role in a company that is applying cutting edge science to areas of unmet medical need. The evolving and significant scientific work and the near term possibility of entering human studies make this a particularly promising time for Senesco. I look forward to helping bring this work to fruition through my interaction with management in my new role."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate a financing; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:
    Senesco Technologies, Inc.
    Bruce Galton
    Chief Executive Officer
    (732) 296-8400

    Investor Relations Contact:
    Brian Ritchie

    Media Relations Contact:
    Irma Gomez-Dib

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
2. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
3. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
4. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
5. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
6. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
7. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
8. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
9. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
10. Senesco Technologies to Present at BIO 2008 Business Forum
11. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Capricor Therapeutics, Inc. ... the discovery, development and commercialization of first-in-class therapeutics, today ... Officer, is scheduled to present at the 2015 Piper ... a.m. EST, at The Lotte New York Palace Hotel ... . --> . ...
(Date:11/24/2015)... INCLINE VILLAGE, Nev. , Nov. 24, 2015  PDL ... John P. McLaughlin , the company,s president and chief ... Piper Jaffray Healthcare Conference next week in New ... and will occur on Tuesday, December 1, 2015 at 9:30 ... and Presentations." Please connect to the website at least 15 ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
(Date:11/23/2015)... , Nov. 24, 2015 Women with a certain ... exams face a higher risk of lung cancer than men ... next week at the annual meeting of the Radiological Society ... --> --> Lung nodules are ... as solid or subsolid based on their appearance on CT. ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
Breaking Biology News(10 mins):